Weight Loss News and Research

Latest Weight Loss News and Research

DARA BioSciences' KRN5500 reduces neuropathic pain in patients with cancer

DARA BioSciences, Inc. today announced the Journal of Pain and Symptom Management, an internationally respected, peer-reviewed journal, has published results of a Phase II safety and efficacy study of KRN5500 for the treatment of neuropathic pain in patients with cancer.

11 Oct 2011

Overweight and blood pressure risk in kids: Study

According to a new study kids who are overweight are nearly three times more likely to have high blood pressure compared to their peers. The study, published in the journal Hypertension, followed 1,111 school-aged children in Indiana for an average of four years.

5 Oct 2011

New research relates role of gender and weight management in overall sleep patterns

The benefits of a good night's sleep to overall health have long been reported. Now, new research has emerged relating to the role gender and weight management play in overall sleep patterns. The abstract, Gender Differences in a Naturalistic Observational Study of Sleep and BMI, was presented during a poster session at the annual Obesity Society meeting in Orlando, Florida this week.

4 Oct 2011

Orexigen presents data from Contrave trial at 29th Annual Scientific Meeting of The Obesity Society

Orexigen Therapeutics, Inc., today announced that Contrave (naltrexone SR/bupropion SR) data will be presented in one oral and multiple poster presentations at the 29th Annual Scientific Meeting of The Obesity Society on October 3, 2011 in Orlando, FL.

4 Oct 2011

Large-scale study on cat intestinal cancer could ultimately benefit humans

A recent, large-scale study on cat intestinal cancer has provided new insight into a common pet disease and its causes; the findings could ultimately benefit humans.

29 Sep 2011

Calif. bill could affect out-patient surgery centers; some Florida public hospitals prosper

Also in news about local hospitals, the Mayo Clinic announces plans to develop a new medical school branch in Arizona and a Minn. hospital is accused of dumping a patient.

29 Sep 2011

First Edition: September 28, 2011

Today's headlines include reports about the costs of employer insurance plans and the final installment of KHN's "Building Ambitions" series about children's hospitals.

28 Sep 2011

Arena, Eisai announce new data from lorcaserin Phase 3 clinical trial program

Arena Pharmaceuticals, Inc. and Eisai Inc. announced today that new data analyses from the lorcaserin Phase 3 clinical trial program will be presented in poster sessions at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society in Orlando, Florida.

27 Sep 2011

Physical activity improves arthritis symptoms in obese mice

Adding another incentive to exercise, scientists at Duke University Medical Center have found that physical activity improves arthritis symptoms even among obese mice that continue to chow down on a high-fat diet.

27 Sep 2011

Sodium Stibogluconate & Paromomycin combination treatment for Kala azar

East Africa is fighting the worst kala azar outbreak in a decade. Collaboration across the region through the Leishmaniasis East Africa Platform (LEAP) has resulted in the development of a new combination therapy (SSG&PM) which is cheaper and nearly halves the length of treatment from a 30 day course of injections to 17 days.

26 Sep 2011

Janssen Biotech receives FDA approval for Remicade to treat UC in children

The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

26 Sep 2011

Ambrx, Bristol-Myers Squibb collaborate for novel biologics to treat heart failure and diabetes

Bristol-Myers Squibb Company and Ambrx, Inc. today announced a collaboration under which Bristol-Myers Squibb will receive exclusive worldwide rights to research, develop and commercialize biologics based on Ambrx's research surrounding the Fibroblast Growth Factor 21 protein, for potential use in treating type 2 diabetes, and the Relaxin hormone, for potential use in treating heart failure.

23 Sep 2011

Anti-obesity drug Contrave may get another chance to prove itself

With rise obesity around the world there should have been a number of drugs to combat it. The reality is different. There are no safe and effective drugs in the market at present.

22 Sep 2011

GI Dynamics introduces EndoBarrier Gastrointestinal Liner in Austria

GI Dynamics, Inc. today announced the launch of the EndoBarrier Gastrointestinal Liner in Austria, the establishment of the first two Centers of Excellence and the treatment of patients at each new Center.

21 Sep 2011

Common symptoms of pediatric feeding disorder

Catering to a child who is a picky eater is like being a short-order cook: chaotic. Dinnertime becomes a war zone, leading to hopeless battles fought over vegetables and macaroni and cheese.

20 Sep 2011

Top-line data from Santarus' budesonide MMX extended use study on ulcerative colitis

Santarus, Inc., a specialty biopharmaceutical company, today announced that analysis of top-line safety data from a double blind, multicenter 12-month extended use study in patients treated daily with either the investigational drug budesonide MMX 6 mg or placebo will be provided as support for the company's planned submission of a New Drug Application (NDA) for budesonide MMX 9 mg to the U.S. Food and Drug Administration (FDA) for the induction of remission of mild or moderate active ulcerative colitis.

20 Sep 2011

California schools bar children without whooping cough shots

...

19 Sep 2011

Nutracheck launches UK's first weight loss App

The UK's first weight loss App that scans barcodes on food products has been launched by Nutracheck.co.uk.

19 Sep 2011

USPTO issues notice of allowance to Cenestra Health's omega-3 fatty acid formulations

The U.S. Patent and Trademark Office (USPTO) has issued a notice of allowance related to Cenestra Health's high-purity omega-3 fatty acid formulations and their methods of use.

19 Sep 2011

Multiple abstracts on QNEXA presented at 47th EASD

VIVUS, Inc. today announced that multiple abstracts were presented at the 47th European Association for the Study of Diabetes (EASD) Annual Meeting in Lisbon, Portugal. The presentations highlighted the long-term beneficial effects of QNEXA treatment in metabolically-impaired patients with prediabetes, diabetes, and metabolic syndrome.

17 Sep 2011